View Future GrowthRead-Gene 과거 순이익 실적과거 기준 점검 2/6Read-Gene의 수입은 연평균 -16.3%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 13.4% 증가했습니다. 매출은 연평균 20.5%의 비율로 증가해 왔습니다. Read-Gene의 자기자본이익률은 63.4%이고 순이익률은 11.8%입니다.핵심 정보-16.28%순이익 성장률-34.40%주당순이익(EPS) 성장률Biotechs 산업 성장률56.32%매출 성장률20.50%자기자본이익률63.43%순이익률11.79%다음 순이익 업데이트12 Aug 2026최근 과거 실적 업데이트Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł0.069 (vs zł0.094 loss in FY 2024)Full year 2025 results: EPS: zł0.069 (up from zł0.094 loss in FY 2024). Revenue: zł15.6m (up 18% from FY 2024). Net income: zł808.3k (up zł1.92m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 11Read-Gene S.A. to Report Q4, 2025 Results on Feb 13, 2026Read-Gene S.A. announced that they will report Q4, 2025 results on Feb 13, 2026Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł3.39m (up 1.6% from 3Q 2024). Net loss: zł237.4k (down 197% from profit in 3Q 2024).공고 • Nov 12Read-Gene S.A. to Report Q3, 2025 Results on Nov 14, 2025Read-Gene S.A. announced that they will report Q3, 2025 results on Nov 14, 2025Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł3.43m (up 16% from 2Q 2024). Net income: zł199.1k (up zł499.2k from 2Q 2024). Profit margin: 5.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł1.47m (down 31% from 1Q 2024). Net loss: zł135.9k (loss narrowed 75% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updates공고 • Jun 09Read-Gene S.A., Annual General Meeting, Jun 30, 2026Read-Gene S.A., Annual General Meeting, Jun 30, 2026.New Risk • Jun 07New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.2% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). High level of non-cash earnings (38% accrual ratio). Minor Risks Revenue is less than US$5m (zł17m revenue, or US$4.5m). Market cap is less than US$100m (zł60.4m market cap, or US$16.4m).New Risk • Feb 24New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.4% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (zł16m revenue, or US$4.3m). Market cap is less than US$100m (zł68.9m market cap, or US$19.2m).Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł0.069 (vs zł0.094 loss in FY 2024)Full year 2025 results: EPS: zł0.069 (up from zł0.094 loss in FY 2024). Revenue: zł15.6m (up 18% from FY 2024). Net income: zł808.3k (up zł1.92m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 11Read-Gene S.A. to Report Q4, 2025 Results on Feb 13, 2026Read-Gene S.A. announced that they will report Q4, 2025 results on Feb 13, 2026New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 62% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (zł15m revenue, or US$4.3m). Market cap is less than US$100m (zł61.3m market cap, or US$17.2m).분석 기사 • Jan 17Is Read-Gene (WSE:RDG) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł3.39m (up 1.6% from 3Q 2024). Net loss: zł237.4k (down 197% from profit in 3Q 2024).공고 • Nov 12Read-Gene S.A. to Report Q3, 2025 Results on Nov 14, 2025Read-Gene S.A. announced that they will report Q3, 2025 results on Nov 14, 2025Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł3.43m (up 16% from 2Q 2024). Net income: zł199.1k (up zł499.2k from 2Q 2024). Profit margin: 5.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (zł14m revenue, or US$3.9m). Market cap is less than US$100m (zł61.5m market cap, or US$16.7m).Buy Or Sell Opportunity • May 27Now 21% overvaluedOver the last 90 days, the stock has fallen 2.6% to zł4.11. The fair value is estimated to be zł3.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has declined by 68%.Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł1.47m (down 31% from 1Q 2024). Net loss: zł135.9k (loss narrowed 75% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.분석 기사 • Nov 27Read-Gene (WSE:RDG) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Aug 13Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł1.07m (down 49% from 2Q 2023). Net loss: zł333.0k (loss narrowed 53% from 2Q 2023).New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (zł11m revenue, or US$2.7m). Market cap is less than US$100m (zł74.3m market cap, or US$18.7m).분석 기사 • Jul 17Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...공고 • Jun 05Read-Gene S.A., Annual General Meeting, Jun 26, 2024Read-Gene S.A., Annual General Meeting, Jun 26, 2024.Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.12m (up 41% from 1Q 2023). Net loss: zł534.9k (loss widened 20% from 1Q 2023).분석 기사 • Feb 14Read-Gene (WSE:RDG) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Feb 13Full year 2023 earnings released: zł0.16 loss per share (vs zł0.018 profit in FY 2022)Full year 2023 results: zł0.16 loss per share (down from zł0.018 profit in FY 2022). Revenue: zł10.1m (up 39% from FY 2022). Net loss: zł1.85m (down zł2.06m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance.공고 • Jan 20+ 4 more updatesRead-Gene S.A. to Report Fiscal Year 2023 Results on May 27, 2024Read-Gene S.A. announced that they will report fiscal year 2023 results at 8:30 AM, Central European Standard Time on May 27, 2024New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Revenue is less than US$5m (zł8.5m revenue, or US$2.1m). Market cap is less than US$100m (zł56.4m market cap, or US$14.0m).New Risk • Aug 23New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (zł38.9m market cap, or US$9.47m). Minor Risk Revenue is less than US$5m (zł7.8m revenue, or US$1.9m).New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (zł7.8m revenue, or US$1.9m). Market cap is less than US$100m (zł43.4m market cap, or US$10.6m).Reported Earnings • Aug 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł2.08m (flat on 2Q 2022). Net loss: zł711.9k (down 290% from profit in 2Q 2022).New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Revenue is less than US$5m (zł7.3m revenue, or US$1.8m). Market cap is less than US$100m (zł41.5m market cap, or US$10.2m).공고 • Jun 04Read-Gene S.A., Annual General Meeting, Jun 30, 2023Read-Gene S.A., Annual General Meeting, Jun 30, 2023, at 15:00 Central European Standard Time.Reported Earnings • Feb 12Full year 2022 earnings released: zł0.015 loss per share (vs zł0.003 profit in FY 2021)Full year 2022 results: zł0.015 loss per share (down from zł0.003 profit in FY 2021). Revenue: zł4.07m (down 37% from FY 2021). Net loss: zł178.6k (down zł216.4k from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings.공고 • Jan 12+ 4 more updatesRead-Gene S.A. to Report Q3, 2023 Results on Nov 10, 2023Read-Gene S.A. announced that they will report Q3, 2023 results on Nov 10, 2023공고 • Jun 07Read-Gene S.A., Annual General Meeting, Jun 30, 2022Read-Gene S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.Reported Earnings • May 16First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł1.00m (down 13% from 1Q 2021). Net loss: zł305.8k (down zł342.8k from profit in 1Q 2021).Reported Earnings • Feb 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: zł6.45m (up 6.3% from FY 2020). Net income: zł342.5k (down 1.9% from FY 2020). Profit margin: 5.3% (down from 5.8% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł1.28m (down 14% from 3Q 2020). Net loss: zł608.1k (down 339% from profit in 3Q 2020).Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł1.35m (up 90% from 2Q 2020). Net income: zł112.8k (up zł535.4k from 2Q 2020). Profit margin: 8.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.Is New 90 Day High Low • Feb 11New 90-day high: zł4.06The company is up 77% from its price of zł2.30 on 13 November 2020. The Polish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 21% over the same period.Is New 90 Day High Low • Jan 21New 90-day high: zł3.02The company is up 14% from its price of zł2.66 on 23 October 2020. The Polish market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 34% over the same period.공고 • Jan 13+ 3 more updatesRead-Gene S.A. to Report Q3, 2021 Results on Nov 14, 2021Read-Gene S.A. announced that they will report Q3, 2021 results on Nov 14, 2021분석 기사 • Dec 17Read-Gene S.A.'s (WSE:RDG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?Read-Gene's (WSE:RDG) stock is up by a considerable 34% over the past three months. Given the company's impressive...매출 및 비용 세부 내역Read-Gene가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이WSE:RDG 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Mar 2617213031 Dec 2516014030 Sep 2513-112030 Jun 2513011031 Mar 2512-111031 Dec 2413-112030 Sep 2413012030 Jun 2412-111031 Mar 2411-111031 Dec 2310-110030 Sep 239-18030 Jun 238-17031 Mar 23806031 Dec 22705030 Sep 22706030 Jun 22706031 Mar 22605031 Dec 21605030 Sep 21705030 Jun 21716031 Mar 21605031 Dec 20604030 Sep 20629030 Jun 20616031 Mar 20716031 Dec 19606030 Sep 19806030 Jun 19806031 Mar 19716031 Dec 18716030 Sep 183-15030 Jun 184-15031 Mar 18405031 Dec 17505030 Sep 176-10030 Jun 175-10031 Mar 17603031 Dec 16500030 Sep 16403030 Jun 16403031 Mar 162-12031 Dec 152-13030 Sep 151-110양질의 수익: RDG의 비현금 수익 수준이 높습니다.이익 마진 증가: RDG는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RDG는 지난 5년 동안 흑자전환하며 연평균 -16.3%의 수익 성장을 기록했습니다.성장 가속화: RDG는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: RDG는 지난해 흑자전환하여 지난 해 수익 성장률을 Biotechs 업계(1.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RDG의 자본 수익률(63.43%)은 뛰어남이지만 높은 부채 수준으로 인해 왜곡되어 있습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 14:59종가2026/07/31 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Read-Gene S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł0.069 (vs zł0.094 loss in FY 2024)Full year 2025 results: EPS: zł0.069 (up from zł0.094 loss in FY 2024). Revenue: zł15.6m (up 18% from FY 2024). Net income: zł808.3k (up zł1.92m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 11Read-Gene S.A. to Report Q4, 2025 Results on Feb 13, 2026Read-Gene S.A. announced that they will report Q4, 2025 results on Feb 13, 2026
Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł3.39m (up 1.6% from 3Q 2024). Net loss: zł237.4k (down 197% from profit in 3Q 2024).
공고 • Nov 12Read-Gene S.A. to Report Q3, 2025 Results on Nov 14, 2025Read-Gene S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł3.43m (up 16% from 2Q 2024). Net income: zł199.1k (up zł499.2k from 2Q 2024). Profit margin: 5.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł1.47m (down 31% from 1Q 2024). Net loss: zł135.9k (loss narrowed 75% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
공고 • Jun 09Read-Gene S.A., Annual General Meeting, Jun 30, 2026Read-Gene S.A., Annual General Meeting, Jun 30, 2026.
New Risk • Jun 07New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.2% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). High level of non-cash earnings (38% accrual ratio). Minor Risks Revenue is less than US$5m (zł17m revenue, or US$4.5m). Market cap is less than US$100m (zł60.4m market cap, or US$16.4m).
New Risk • Feb 24New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.4% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (zł16m revenue, or US$4.3m). Market cap is less than US$100m (zł68.9m market cap, or US$19.2m).
Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł0.069 (vs zł0.094 loss in FY 2024)Full year 2025 results: EPS: zł0.069 (up from zł0.094 loss in FY 2024). Revenue: zł15.6m (up 18% from FY 2024). Net income: zł808.3k (up zł1.92m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 11Read-Gene S.A. to Report Q4, 2025 Results on Feb 13, 2026Read-Gene S.A. announced that they will report Q4, 2025 results on Feb 13, 2026
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 62% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (zł15m revenue, or US$4.3m). Market cap is less than US$100m (zł61.3m market cap, or US$17.2m).
분석 기사 • Jan 17Is Read-Gene (WSE:RDG) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł3.39m (up 1.6% from 3Q 2024). Net loss: zł237.4k (down 197% from profit in 3Q 2024).
공고 • Nov 12Read-Gene S.A. to Report Q3, 2025 Results on Nov 14, 2025Read-Gene S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł3.43m (up 16% from 2Q 2024). Net income: zł199.1k (up zł499.2k from 2Q 2024). Profit margin: 5.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (zł14m revenue, or US$3.9m). Market cap is less than US$100m (zł61.5m market cap, or US$16.7m).
Buy Or Sell Opportunity • May 27Now 21% overvaluedOver the last 90 days, the stock has fallen 2.6% to zł4.11. The fair value is estimated to be zł3.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has declined by 68%.
Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł1.47m (down 31% from 1Q 2024). Net loss: zł135.9k (loss narrowed 75% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
분석 기사 • Nov 27Read-Gene (WSE:RDG) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Aug 13Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł1.07m (down 49% from 2Q 2023). Net loss: zł333.0k (loss narrowed 53% from 2Q 2023).
New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (zł11m revenue, or US$2.7m). Market cap is less than US$100m (zł74.3m market cap, or US$18.7m).
분석 기사 • Jul 17Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
공고 • Jun 05Read-Gene S.A., Annual General Meeting, Jun 26, 2024Read-Gene S.A., Annual General Meeting, Jun 26, 2024.
Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.12m (up 41% from 1Q 2023). Net loss: zł534.9k (loss widened 20% from 1Q 2023).
분석 기사 • Feb 14Read-Gene (WSE:RDG) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Feb 13Full year 2023 earnings released: zł0.16 loss per share (vs zł0.018 profit in FY 2022)Full year 2023 results: zł0.16 loss per share (down from zł0.018 profit in FY 2022). Revenue: zł10.1m (up 39% from FY 2022). Net loss: zł1.85m (down zł2.06m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance.
공고 • Jan 20+ 4 more updatesRead-Gene S.A. to Report Fiscal Year 2023 Results on May 27, 2024Read-Gene S.A. announced that they will report fiscal year 2023 results at 8:30 AM, Central European Standard Time on May 27, 2024
New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Revenue is less than US$5m (zł8.5m revenue, or US$2.1m). Market cap is less than US$100m (zł56.4m market cap, or US$14.0m).
New Risk • Aug 23New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (zł38.9m market cap, or US$9.47m). Minor Risk Revenue is less than US$5m (zł7.8m revenue, or US$1.9m).
New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (zł7.8m revenue, or US$1.9m). Market cap is less than US$100m (zł43.4m market cap, or US$10.6m).
Reported Earnings • Aug 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł2.08m (flat on 2Q 2022). Net loss: zł711.9k (down 290% from profit in 2Q 2022).
New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Revenue is less than US$5m (zł7.3m revenue, or US$1.8m). Market cap is less than US$100m (zł41.5m market cap, or US$10.2m).
공고 • Jun 04Read-Gene S.A., Annual General Meeting, Jun 30, 2023Read-Gene S.A., Annual General Meeting, Jun 30, 2023, at 15:00 Central European Standard Time.
Reported Earnings • Feb 12Full year 2022 earnings released: zł0.015 loss per share (vs zł0.003 profit in FY 2021)Full year 2022 results: zł0.015 loss per share (down from zł0.003 profit in FY 2021). Revenue: zł4.07m (down 37% from FY 2021). Net loss: zł178.6k (down zł216.4k from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings.
공고 • Jan 12+ 4 more updatesRead-Gene S.A. to Report Q3, 2023 Results on Nov 10, 2023Read-Gene S.A. announced that they will report Q3, 2023 results on Nov 10, 2023
공고 • Jun 07Read-Gene S.A., Annual General Meeting, Jun 30, 2022Read-Gene S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.
Reported Earnings • May 16First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł1.00m (down 13% from 1Q 2021). Net loss: zł305.8k (down zł342.8k from profit in 1Q 2021).
Reported Earnings • Feb 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: zł6.45m (up 6.3% from FY 2020). Net income: zł342.5k (down 1.9% from FY 2020). Profit margin: 5.3% (down from 5.8% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.
Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł1.28m (down 14% from 3Q 2020). Net loss: zł608.1k (down 339% from profit in 3Q 2020).
Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł1.35m (up 90% from 2Q 2020). Net income: zł112.8k (up zł535.4k from 2Q 2020). Profit margin: 8.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.
Is New 90 Day High Low • Feb 11New 90-day high: zł4.06The company is up 77% from its price of zł2.30 on 13 November 2020. The Polish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 21% over the same period.
Is New 90 Day High Low • Jan 21New 90-day high: zł3.02The company is up 14% from its price of zł2.66 on 23 October 2020. The Polish market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 34% over the same period.
공고 • Jan 13+ 3 more updatesRead-Gene S.A. to Report Q3, 2021 Results on Nov 14, 2021Read-Gene S.A. announced that they will report Q3, 2021 results on Nov 14, 2021
분석 기사 • Dec 17Read-Gene S.A.'s (WSE:RDG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?Read-Gene's (WSE:RDG) stock is up by a considerable 34% over the past three months. Given the company's impressive...